Structure-Activity Relationship of 4,6-Disubstituted Pyrimidines as EGFR and VEGFR-2 Tyrosine Kinase Inhibitors

被引：2
作者：
Song, Jiho [1 ]
Lee, Jung Wook [1 ]
Chung, Shin Hyuck [1 ]
Wenas, Michelle A. [1 ]
Min, Kyung Hoon [1 ]
机构：
[1] Chung Ang Univ, Coll Pharm, Seoul 06974, South Korea
来源：
BULLETIN OF THE KOREAN CHEMICAL SOCIETY | 2017年 / 38卷 / 11期
基金：
新加坡国家研究基金会;
关键词：
EGFR; VEGFR-2; Tyrosine kinase inhibitors; Pyrimidine; GROWTH-FACTOR RECEPTOR; BEVACIZUMAB; ERLOTINIB; CANCER; RESISTANCE; THERAPY; CELL;
D O I：
10.1002/bkcs.11278
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
[No abstract available]
引用
收藏
页码：1255 / 1256
页数：2
相关论文
共 10 条
[1]   Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model [J].
Bozec, A. ;
Sudaka, A. ;
Fischel, J-L ;
Brunstein, M-C ;
Etienne-Grimaldi, M-C ;
Milano, G. .
BRITISH JOURNAL OF CANCER, 2008, 99 (01) :93-99
[2]   Ten years of anti-vascular endothelial growth factor therapy [J].
Ferrara, Napoleone ;
Adamis, Anthony P. .
NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (06) :385-403
[3]   [4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors [J].
Garofalo, Antonio ;
Goossens, Laurence ;
Lemoine, Amelie ;
Ravez, Severine ;
Six, Perdue ;
Howsam, Michael ;
Farce, Amaury ;
Depreux, Patrick .
MEDCHEMCOMM, 2011, 2 (01) :65-72
[4]   VEGF targets the tumour cell [J].
Goel, Hira Lal ;
Mercurio, Arthur M. .
NATURE REVIEWS CANCER, 2013, 13 (12) :871-882
[5]   Mechanisms of resistance to EGFR tyrosine kinase inhibitors [J].
Huang, Lihua ;
Fu, Liwu .
ACTA PHARMACEUTICA SINICA B, 2015, 5 (05) :390-401
[6]   Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance [J].
Naumov, George N. ;
Nilsson, Monique B. ;
Cascone, Tina ;
Briggs, Alexandra ;
Straume, Oddbjorn ;
Akslen, Lars A. ;
Lifshits, Eugene ;
Byers, Lauren Averett ;
Xu, Li ;
Wu, Hua-Kang ;
Janne, Pasi ;
Kobayashi, Susumu ;
Halmos, Balazs ;
Tenen, Daniel ;
Tang, Xi M. ;
Engelman, Jeffrey ;
Yeap, Beow ;
Folkman, Judah ;
Johnson, Bruce E. ;
Heymach, John V. .
CLINICAL CANCER RESEARCH, 2009, 15 (10) :3484-3494
[7]   Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma [J].
Schicher, Nikolaus ;
Paulitschke, Verena ;
Swoboda, Alexander ;
Kunstfeld, Rainer ;
Loewe, Robert ;
Pilarski, Peter ;
Pehamberger, Hubert ;
Hoeller, Christoph .
CLINICAL CANCER RESEARCH, 2009, 15 (10) :3495-3502
[8]   Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study [J].
Seto, Takashi ;
Kato, Terufumi ;
Nishio, Makoto ;
Goto, Koichi ;
Atagi, Shinji ;
Hosomi, Yukio ;
Yamamoto, Noboru ;
Hida, Toyoaki ;
Maemondo, Makoto ;
Nakagawa, Kazuhiko ;
Nagase, Seisuke ;
Okamoto, Isamu ;
Yamanaka, Takeharu ;
Tajima, Kosei ;
Harada, Ryosuke ;
Fukuoka, Masahiro ;
Yamamoto, Nobuyuki .
LANCET ONCOLOGY, 2014, 15 (11) :1236-1244
[9]   Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases [J].
Song, Jiho ;
Yoo, Jakyung ;
Kwon, Ara ;
Kim, Doran ;
Hong Khanh Nguyen ;
Lee, Bong-Yong ;
Suh, Wonhee ;
Min, Kyung Hoon .
PLOS ONE, 2015, 10 (09)
[10]   Epidermal growth factor receptor targeting in cancer: A review of trends and strategies [J].
Yewale, Chetan ;
Baradia, Dipesh ;
Vhora, Imran ;
Patil, Sushilkumar ;
Misra, Ambikanandan .
BIOMATERIALS, 2013, 34 (34) :8690-8707
1